AxoGen (AXGN) Competitors

$41.95 +0.96 (+2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$41.99 +0.04 (+0.10%)

As of 07:57 PM Eastern

AXGN vs. GKOS, BLCO, STVN, IRTC, and LIVN

Should you buy AxoGen stock or one of its competitors? MarketBeat compares AxoGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AxoGen include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does AxoGen compare to Glaukos?

AxoGen (NASDAQ:AXGN) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Glaukos	-34.34%	-6.92%	-5.25%

AxoGen has higher earnings, but lower revenue than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.91	-$15.70M	-$0.64	N/A
Glaukos	$507.44M	16.48	-$187.69M	-$3.28	N/A

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, AxoGen had 5 more articles in the media than Glaukos. MarketBeat recorded 11 mentions for AxoGen and 6 mentions for Glaukos. AxoGen's average media sentiment score of 0.96 beat Glaukos' score of 0.56 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 10.85%. Glaukos has a consensus price target of $144.42, indicating a potential upside of 1.39%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Glaukos beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to Bausch + Lomb?

AxoGen (NASDAQ:AXGN) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, AxoGen had 5 more articles in the media than Bausch + Lomb. MarketBeat recorded 11 mentions for AxoGen and 6 mentions for Bausch + Lomb. AxoGen's average media sentiment score of 0.96 beat Bausch + Lomb's score of 0.11 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Bausch + Lomb	-4.21%	3.60%	1.69%

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 10.85%. Bausch + Lomb has a consensus price target of $18.08, suggesting a potential upside of 12.33%. Given Bausch + Lomb's higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

AxoGen has higher earnings, but lower revenue than Bausch + Lomb. AxoGen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.91	-$15.70M	-$0.64	N/A
Bausch + Lomb	$5.10B	1.13	-$360M	-$0.62	N/A

Summary

AxoGen beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to Stevanato Group?

AxoGen (NASDAQ:AXGN) and Stevanato Group (NYSE:STVN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

AxoGen has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Stevanato Group has a net margin of 11.76% compared to AxoGen's net margin of -13.21%. Stevanato Group's return on equity of 10.27% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Stevanato Group	11.76%	10.27%	6.08%

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.91	-$15.70M	-$0.64	N/A
Stevanato Group	€1.34B	4.02	€158.21M	€0.59	30.17

In the previous week, AxoGen had 10 more articles in the media than Stevanato Group. MarketBeat recorded 11 mentions for AxoGen and 1 mentions for Stevanato Group. AxoGen's average media sentiment score of 0.96 beat Stevanato Group's score of 0.00 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen currently has a consensus target price of $46.50, indicating a potential upside of 10.85%. Given AxoGen's stronger consensus rating and higher possible upside, analysts plainly believe AxoGen is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

AxoGen beats Stevanato Group on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to iRhythm Technologies?

AxoGen (NASDAQ:AXGN) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

iRhythm Technologies has a net margin of -3.53% compared to AxoGen's net margin of -13.21%. AxoGen's return on equity of -9.63% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 10.85%. iRhythm Technologies has a consensus price target of $191.85, indicating a potential upside of 72.93%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, AxoGen had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 11 mentions for AxoGen and 9 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.34 beat AxoGen's score of 0.96 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.91	-$15.70M	-$0.64	N/A
iRhythm Technologies	$747.14M	4.88	-$44.55M	-$0.86	N/A

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

iRhythm Technologies beats AxoGen on 9 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

AxoGen (NASDAQ:AXGN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

In the previous week, AxoGen had 9 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for AxoGen and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.98 beat AxoGen's score of 0.96 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.91	-$15.70M	-$0.64	N/A
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.04

AxoGen has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

80.3% of AxoGen shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
LivaNova	7.48%	16.48%	7.59%

AxoGen presently has a consensus target price of $46.50, suggesting a potential upside of 10.85%. LivaNova has a consensus target price of $77.22, suggesting a potential upside of 6.91%. Given AxoGen's higher possible upside, equities research analysts clearly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
LivaNova	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

LivaNova beats AxoGen on 9 of the 16 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.18B	$6.75B	$6.25B	$12.28B
Dividend Yield	N/A	1.76%	2.80%	5.30%
P/E Ratio	-65.55	49.87	20.86	25.24
Price / Sales	9.91	71.35	549.88	74.54
Price / Cash	N/A	24.43	27.48	37.27
Price / Book	15.04	6.54	9.67	6.63
Net Income	-$15.70M	$158.81M	$3.56B	$335.41M
7 Day Performance	2.84%	-1.03%	-1.91%	-1.83%
1 Month Performance	8.96%	-5.70%	-2.65%	-1.16%
1 Year Performance	254.61%	-3.78%	31.17%	28.31%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	3.1867 of 5 stars	$41.95 +2.3%	$46.50 +10.8%	+246.5%	$2.18B	$225.21M	N/A	450
GKOS Glaukos	2.5257 of 5 stars	$135.17 +1.2%	$144.42 +6.8%	+50.4%	$7.84B	$507.44M	N/A	1,094	Insider Trade
BLCO Bausch + Lomb	4.3455 of 5 stars	$16.10 -0.5%	$18.08 +12.3%	+36.7%	$5.77B	$5.21B	N/A	13,000
STVN Stevanato Group	2.9791 of 5 stars	€18.29 +0.1%	N/A	-25.9%	€5.54B	€1.34B	31.00	6,010
IRTC iRhythm Technologies	4.5815 of 5 stars	$116.84 -3.2%	$193.38 +65.5%	-19.1%	$3.97B	$747.14M	N/A	2,400	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors

AXGN vs. GKOS, BLCO, STVN, IRTC, and LIVN

How does AxoGen compare to Glaukos?

Summary

How does AxoGen compare to Bausch + Lomb?

Summary

How does AxoGen compare to Stevanato Group?

Summary

How does AxoGen compare to iRhythm Technologies?

Summary

How does AxoGen compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AxoGen (AXGN) Competitors

AXGN vs. GKOS, BLCO, STVN, IRTC, and LIVN

How does AxoGen compare to Glaukos?

Is AXGN or GKOS more profitable?

Which has higher earnings & valuation, AXGN or GKOS?

Do institutionals & insiders hold more shares of AXGN or GKOS?

Does the media favor AXGN or GKOS?

Which has more volatility and risk, AXGN or GKOS?

Do analysts prefer AXGN or GKOS?

Summary

How does AxoGen compare to Bausch + Lomb?

Which has more risk and volatility, AXGN or BLCO?

Does the media favor AXGN or BLCO?

Do insiders & institutionals believe in AXGN or BLCO?

Is AXGN or BLCO more profitable?

Do analysts rate AXGN or BLCO?

Which has stronger valuation and earnings, AXGN or BLCO?

Summary

How does AxoGen compare to Stevanato Group?

Which has more volatility and risk, AXGN or STVN?

Is AXGN or STVN more profitable?

Which has higher valuation and earnings, AXGN or STVN?

Does the media prefer AXGN or STVN?

Do analysts prefer AXGN or STVN?

Do institutionals & insiders believe in AXGN or STVN?

Summary

How does AxoGen compare to iRhythm Technologies?

Is AXGN or IRTC more profitable?

Do analysts prefer AXGN or IRTC?

Does the media prefer AXGN or IRTC?

Which has preferable valuation & earnings, AXGN or IRTC?

Do institutionals and insiders believe in AXGN or IRTC?

Which has more risk & volatility, AXGN or IRTC?

Summary

How does AxoGen compare to LivaNova?

Does the media prefer AXGN or LIVN?

Which has better earnings & valuation, AXGN or LIVN?

Which has more risk and volatility, AXGN or LIVN?

Do institutionals & insiders hold more shares of AXGN or LIVN?

Is AXGN or LIVN more profitable?

Do analysts rate AXGN or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools